MyOme and Collective Health® Partner to Expand Access to MyOme’s Whole-Genome Based Products for Employers

The new joint initiative with The Partner Collective® by Collective Health® will allow employers to empower their workforces with MyOme’s lifelong genomic insights to support preventative care and personalized health decisions.

MENLO PARK, Calif., May 7, 2025 /PRNewswire/ — MyOme, a leading whole-genome analysis and polygenic risk modeling (PRS) company, announced that it has joined The Partner Collective® by Collective Health®— a digital health partner hub that helps employers, brokers, and consultants discover and engage with innovative benefits offerings.

With this collaboration, MyOme becomes part of a select ecosystem of high-impact solutions designed to improve workforce health outcomes through proactive care. MyOme’s platform delivers actionable insights through clinical-grade whole-genome sequencing (WGS) analyses— empowering individuals with genetic insights that can identify risk for both rare and common diseases.

As a member of The Partner Collective, MyOme’s suite of whole-genome based products is now more accessible to forward-thinking employers looking to integrate cutting-edge, personalized, and preventative health tools into their employee benefits. By enabling early risk identification for top employer cost drivers, MyOme helps organizations optimally address root causes of chronic illness and support healthier, more engaged employees. With insights that inform prevention and early intervention, employers can improve long-term outcomes while reducing overall healthcare spend.

Key Benefits of the MyOme Solution for Employers:

• Comprehensive, Inclusive Genomics
  MyOme uses whole-genome sequencing—the most complete view of a person’s DNA—paired with advanced, industry-leading analytics to deliver clinically actionable insights. Validated across diverse and ad-mixed populations, MyOme’s products support equitable care and are ready to scale with a growing menu of disease types.
• Smarter Care, Lower Costs
  MyOme helps employers tackle top healthcare cost drivers like cancer, cardiovascular disease, and diabetes. By identifying risk earlier and guiding targeted prevention, we help optimize use of high-cost care plans, screening tools, and therapeutics to improve long-term outcomes—translating to healthier employees and reduced medical spend.
• End-to-End Support including Genetic Counseling
  Employees aren’t left to navigate results alone. MyOme includes access to certified genetic counselors and personalized educational tools, empowering individuals to understand their health risks and take informed next steps alongside their providers.

“Joining The Partner Collective allows us to connect with benefits leaders committed to transforming employee health through innovation,” said Yasser Ads, MD, Chief Business Officer at MyOme. “Our goal is to make genomic insights clinically useful, equitable, and accessible — ultimately supporting healthier, more informed populations.”

MyOme’s inclusion in The Partner Collective reflects a shared commitment to making cutting-edge, preventative care accessible across diverse populations and workforces.

Learn more about The Partner Collective: https://collectivehealth.com/partner-collective/

About MyOme
MyOme^® is a clinical whole-genome analysis company helping individuals and families understand their risk for inherited disease. As a leader in polygenic risk modeling, MyOme delivers lifetime insights through a single whole-genome test. CLIA- and CAP-certified, MyOme is headquartered in Menlo Park, California. Learn more at www.myome.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/myome-and-collective-health-partner-to-expand-access-to-myomes-whole-genome-based-products-for-employers-302448266.html

SOURCE MyOme, Inc